OBJECTIVE: To investigate feasibility and safety of stereotactic ablative radiotherapy in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial marker seeds for positioning and Varian RapidArc with flattening filter free (FFF) delivery. METHODS: 41 patients were treated for low-intermediate risk prostate cancer with initial prostate-specific antigen of ≤20 ng ml-1, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate ±seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality. Verification on treatment was cone beam CT imaging with fiducial markers for matching. Patients had Radiation Therapy Oncology Group scoring for genitourinary and gastointestinal symptoms at baseline, week 4, 10 and 18. RESULTS: Clinically acceptable plans were achieved for all patients, all plans achieved the objective clinical target volume D99% ≥ 95%, and for planning target volume D95% ≥ 95%. Rectum dose constraints were met for 95.1% for V18 Gy ≤ 35%, 80% V28 Gy ≤ 10%. A total of 32 (78.0%) plans achieved all rectum dose constraints. Grade 1 acute genitourinary symptoms were 53.7% of patients at baseline, 90.2% [95% CI (76.8-97.3%)] (p = 0.0005) at treatment 5, falling to 78.0% (62.4-89.4%) at week 4, and 75.0% (58.8-87.3%) by week 10 and 52.5% (36.1-68.5%) (p = 1.00) at week 18. Acute gastrointestinal symptoms were 5% at baseline, 46.3% [95% CI (30.7-62.6%)] at treatment 5, week 4 43.9% [95% CI (28.5-60.3%)], week 10 25.0% (11.1-42.3%), and declined slightly by week 18 [-20.095% CI (12.7-41.2)] p = 0.039. Overall 75.6% (31/41) of patients experienced Grade 1-2 toxicity during or after treatment. CONCLUSION: This planning and delivery technique is feasible, safe and efficient. A homogeneous dose can be delivered to prostate with confidence, whilst limiting high dose to nearby structures. The use of this technology can be applied safely within further randomized study protocols. Advances in knowledge: Multimodality imaging for delineation and linac-based image-guided RT with FFF for the treatment of prostate stereotactic ablative radiotherapy.
OBJECTIVE: To investigate feasibility and safety of stereotactic ablative radiotherapy in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial marker seeds for positioning and Varian RapidArc with flattening filter free (FFF) delivery. METHODS: 41 patients were treated for low-intermediate risk prostate cancer with initial prostate-specific antigen of ≤20 ng ml-1, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate ±seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality. Verification on treatment was cone beam CT imaging with fiducial markers for matching. Patients had Radiation Therapy Oncology Group scoring for genitourinary and gastointestinal symptoms at baseline, week 4, 10 and 18. RESULTS: Clinically acceptable plans were achieved for all patients, all plans achieved the objective clinical target volume D99% ≥ 95%, and for planning target volume D95% ≥ 95%. Rectum dose constraints were met for 95.1% for V18 Gy ≤ 35%, 80% V28 Gy ≤ 10%. A total of 32 (78.0%) plans achieved all rectum dose constraints. Grade 1 acute genitourinary symptoms were 53.7% of patients at baseline, 90.2% [95% CI (76.8-97.3%)] (p = 0.0005) at treatment 5, falling to 78.0% (62.4-89.4%) at week 4, and 75.0% (58.8-87.3%) by week 10 and 52.5% (36.1-68.5%) (p = 1.00) at week 18. Acute gastrointestinal symptoms were 5% at baseline, 46.3% [95% CI (30.7-62.6%)] at treatment 5, week 4 43.9% [95% CI (28.5-60.3%)], week 10 25.0% (11.1-42.3%), and declined slightly by week 18 [-20.095% CI (12.7-41.2)] p = 0.039. Overall 75.6% (31/41) of patients experienced Grade 1-2 toxicity during or after treatment. CONCLUSION: This planning and delivery technique is feasible, safe and efficient. A homogeneous dose can be delivered to prostate with confidence, whilst limiting high dose to nearby structures. The use of this technology can be applied safely within further randomized study protocols. Advances in knowledge: Multimodality imaging for delineation and linac-based image-guided RT with FFF for the treatment of prostate stereotactic ablative radiotherapy.
Authors: Cai Grau; Noémie Defourny; Julian Malicki; Peter Dunscombe; Josep M Borras; Mary Coffey; Ben Slotman; Marta Bogusz; Chiara Gasparotto; Yolande Lievens; Arianit Kokobobo; Felix Sedlmayer; Elena Slobina; Karen Feyen; Tatiana Hadjieva; Karel Odrazka; Jesper Grau Eriksen; Jana Jaal; Ritva Bly; Bruno Chauvet; Normann Willich; Csaba Polgar; Jakob Johannsson; Moya Cunningham; Stefano Magrini; Vydmantas Atkocius; Michel Untereiner; Martin Pirotta; Vanja Karadjinovic; Sverre Levernes; Krystol Sladowski; Maria Lurdes Trigo; Barbara Šegedin; Aurora Rodriguez; Magnus Lagerlund; Bert Pastoors; Peter Hoskin; Jaap Vaarkamp; Ramon Cleries Soler Journal: Radiother Oncol Date: 2014-10-31 Impact factor: 6.280
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-15 Impact factor: 7.038
Authors: Christopher R King; James D Brooks; Harcharan Gill; Joseph C Presti Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-06 Impact factor: 7.038
Authors: Andrew Loblaw; Patrick Cheung; Laura D'Alimonte; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Colin Tang; Harvey Quon; Suneil Jain; Geordi Pang; Robert Nam Journal: Radiother Oncol Date: 2013-05-03 Impact factor: 6.280
Authors: Christopher R King; James D Brooks; Harcharan Gill; Todd Pawlicki; Cristian Cotrutz; Joseph C Presti Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-26 Impact factor: 7.038
Authors: David P Dearnaley; Matthew R Sydes; Ruth E Langley; John D Graham; Robert A Huddart; Isabel Syndikus; John H L Matthews; Christopher D Scrase; Chakiath C Jose; John Logue; Richard J Stephens Journal: Radiother Oncol Date: 2007-03-27 Impact factor: 6.280